86 results
PRE 14A
PRAX
Praxis Precision Medicines Inc
4 Oct 23
Preliminary proxy
7:56am
, will arise as a result of the Reverse Stock Split.
Certain U.S. Federal Income Tax Consequences of the Reverse Stock Split
The following discussion … is a summary of certain U.S. federal income tax consequences of the Reverse Stock Split to that may be relevant to U.S. Holders (as defined below
424B5
PRAX
Praxis Precision Medicines Inc
12 Jan 24
Prospectus supplement for primary offering
5:20pm
DESCRIPTION OF PRE-FUNDED WARRANTS
S-13
MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES
S-15
UNDERWRITING
S-21
LEGAL MATTERS
S-29
EXPERTS
S-29
WHERE YOU CAN … , including any voting rights, until such holder exercises the pre-funded warrants.
S-14
MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES
The following
424B5
PRAX
Praxis Precision Medicines Inc
20 Jun 23
Prospectus supplement for primary offering
6:02am
STATEMENTS
S-8
USE OF PROCEEDS
S-10
DIVIDEND POLICY
S-11
DESCRIPTION OF PRE-FUNDED WARRANTS
S-12
MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S … any voting rights, until such holder exercises the pre-funded warrants.
S-13
MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES
The following discussion
424B5
PRAX
Praxis Precision Medicines Inc
15 Jun 23
Prospectus supplement for primary offering
5:26pm
-8
DIVIDEND POLICY
S-9
DILUTION
S-10
MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS OF
OUR COMMON STOCK
S-11
UNDERWRITING
S-15 … , there will be further dilution to investors participating in this offering.
S-10
MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS
424B5
PRAX
Praxis Precision Medicines Inc
29 Mar 24
Prospectus supplement for primary offering
4:29pm
DIVIDEND POLICY
S-10
DILUTION
S-11
DESCRIPTION OF PRE-FUNDED WARRANTS
S-13
MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES
S-15
UNDERWRITING
S-21
LEGAL … of our common stock, including any voting rights, until such holder exercises the pre-funded warrants.
S-14
MATERIAL U.S. FEDERAL INCOME TAX
424B5
kiwckiixxog b1
27 Mar 24
Prospectus supplement for primary offering
4:49pm
424B5
qcolhi l5wjxi
10 Jan 24
Prospectus supplement for primary offering
5:28pm
424B4
pumlj
14 May 21
Prospectus supplement with pricing info
4:34pm
DRS
tr2nap
18 Mar 21
Draft registration statement
12:00am
S-1
EX-10.12
8rwdlscpvmua54
25 Sep 20
IPO registration
5:19pm
10-Q
EX-10.11
ofpozj4nb4sbf43lu6
23 Nov 20
Quarterly report
4:16pm
DRS
EX-10.3
m9jjolr37 85u
22 Jul 20
Draft registration statement
12:00am
FWP
5u1zcfabbghdhwo9y
15 Jun 23
Free writing prospectus
9:44pm